Hepatocellular Carcinoma study: Pumitamig vs Ipilimumab
Official title A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
ClinicalTrials.gov ID: NCT07291076
What this study is testing
What is Pumitamig?
This is an investigational medicine being studied to see if it can help treat advanced liver cancer.
Also referred to as BMS-986545.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if the drug Pumitamig is safe and how well people tolerate it, either by itself or combined with Ipilimumab.
- Who it's for
- People with advanced liver cancer that cannot be removed by surgery who have not started treatment yet.
- What's involved
- Participants will receive Pumitamig, either alone or with Ipilimumab, and undergo regular medical checks to monitor their health.
- Time commitment
- The source text does not specify the duration or visit schedule.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have no prior systemic therapy for advanced/ unresectable HCC.
- Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You likely can't join if
- Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.
- Participants must not have an organ transplant or autoimmune disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Duarte, California, United States
- Hackensack, New Jersey, United States
- Mineola, New York, United States
- Portland, Oregon, United States
- Nashville, Tennessee, United States
- Camperdown, New South Wales, Australia
- Birtinya, Queensland, Australia
- Parkville, Victoria, Australia
- Santiago, Santiago Metropolitan, Chile
- Santiago Region Metropolitana, Santiago Metropolitan, Chile
- Pessac, Aquitaine, France
- La Tronche, Auvergne-Rhône-Alpes, France
- Montpellier, Languedoc-Roussillon, France
- Saint Priest En Jarez, Pays de la Loire Region, France
- Bobigny, France
- Cologne, North Rhine-Westphalia, Germany
- Lübeck, Schleswig-Holstein, Germany
- Frankfurt, Germany
- Mainz, Germany
- Meldola, Emilia-Romagna, Italy
+ 13 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Duarte, California, United States; Hackensack, New Jersey, United States; Mineola, New York, United States; Portland, Oregon, United States; Nashville, Tennessee, United States; Camperdown, New South Wales, Australia and 27 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.